1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        APAC Non-Alcoholic Steatohepatitis Market – By Product

1.3.2        APAC Non-Alcoholic Steatohepatitis Market – By Application

1.3.3        APAC Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4        APAC Non-Alcoholic Steatohepatitis Market – By Country

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           APAC Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Asia Pacific PEST Analysis

4.3         Experts Opinion

5.           APAC Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rising Prevalence of NASH

5.1.2        Increasing Initiatives for the Awareness of NASH

5.2         Market Restraints

5.2.1        Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2        Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3         Market Opportunities

5.3.1        Growing Opportunities in Developing Nations

5.3.2        High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4         Future Trends

5.4.1        Growing Clinical Trials Involving Combination Studies of Drugs

5.5         Impact Analysis

6.           Non-alcoholic steatohepatitis (NASH) Market– APAC Analysis

6.1         APAC Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

7.           APAC Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1         Overview

7.2         Product Market Revenue and Forecast Analysis (US$ Mn)

7.3         Vitamin E and Pioglitazone

7.3.1        Overview

7.3.2        Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4         Ocaliva

7.4.1        Overview

7.4.2        Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5         Elafibranor

7.5.1        Overview

7.5.2        Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6         Selonsertib & Cenicriviroc

7.6.1        Overview

7.6.2        Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7         Others

7.7.1        Overview

7.7.2        Others Revenue and Forecast to 2028 (US$ Mn)

8.           APAC Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1         Overview

8.2         Application Market Revenue and Forecast Analysis (US$ Mn)

8.3         Treatment

8.3.1        Overview

8.3.2        Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4         Diagnosis

8.4.1        Overview

8.4.2        Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9.           APAC Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1         Overview

9.2         Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3         Hospital Pharmacy

9.3.1        Overview

9.3.2        Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4         Retail Pharmacy

9.4.1        Overview

9.4.2        Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5         Online Provider

9.5.1        Overview

9.5.2        Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10.        APAC Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis

10.1      Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecasts To 2028

10.1.1     Overview

10.1.3     Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

10.1.3.1       China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.1.1       China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.1.2       China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.1.3.1.3       China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.1.3.1.4       China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.1.3.2       Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.2.1       Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.2.2       Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.1.3.2.3       Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.1.3.2.4       Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.1.3.3       India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.3.1       India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.3.2       India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.1.3.3.3       India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.1.3.3.4       India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.1.3.4       Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.4.1       Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.4.2       Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.1.3.4.3       Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.1.3.4.4       Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.1.3.5       South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.5.1       South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.5.2       South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.1.3.5.3       South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.1.3.5.4       South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.1.3.6       Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.6.1       Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.6.2       Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.1.3.6.3       Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.1.3.6.4       Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

11.        Industry Landscape

11.1      Overview

11.2      Organic Developments

11.2.1     Overview

11.3      Inorganic Developments

11.3.1     Overview

12.        Company Profiles

12.1      Cadila Pharmaceuticals Ltd.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Intercept Pharmaceuticals, Inc

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      Novartis AG

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      Galmed Pharmaceuticals.

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      GENFIT.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      Siemens Healthineers AG

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7      Laboratory Corporation of America Holdings

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

13.        Appendix

13.1      About The Insight Partners

13.2      Glossary of Terms

LIST OF TABLES

Table 1.             China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 2.             China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 3.             China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 4.             Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 5.             Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 6.             Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 7.             India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 8.             India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 9.             India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 10.          Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 11.          Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 12.          Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 13.          South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 14.          South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 15.          South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 16.          Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 17.          Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 18.          Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 19.          Organic Developments Done By Companies

Table 20.          Inorganic Developments Done By Companies

Table 21.          Glossary of Terms

LIST OF FIGURES

Figure 1.           APAC Non-Alcoholic Steatohepatitis Market Segmentation

Figure 2.           APAC Non-Alcoholic Steatohepatitis Market, By Country

Figure 3.           APAC Non-Alcoholic Steatohepatitis Market Overview

Figure 4.           APAC Non-Alcoholic Steatohepatitis Market, By Application

Figure 5.           APAC Non-Alcoholic Steatohepatitis Market, By Country

Figure 6.           Asia Pacific: PEST Analysis

Figure 7.           APAC Experts Opinion

Figure 8.           APAC Non-Alcoholic Steatohepatitis (NASH) Market Impact Analysis of Drivers and Restraints

Figure 9.           APAC Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis

Figure 10.        APAC Product Market Analysis and Forecast 2021 and 2028 (%)

Figure 11.        APAC Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

Figure 12.        APAC Ocaliva Revenue and Forecast to 2028 (US$ Mn)

Figure 13.        APAC Elafibranor Revenue and Forecast to 2028 (US$ Mn)

Figure 14.        APAC Selonsertib Revenue and Forecast to 2028 (US$ Mn)

Figure 15.        APAC Others Revenue and Forecast to 2028 (US$ Mn)

Figure 16.        Application Market Analysis and Forecast 2021 and 2028 (%)

Figure 17.        APAC Treatment Market Revenue and Forecast to 2028 (US$ Mn)

Figure 18.        APAC Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

Figure 19.        APAC Sales Channel Market Analysis and Forecast 2021 and 2028 (%)

Figure 20.        Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 21.        APAC Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 22.        APAC Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

Figure 23.        Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Key Country – Revenue (2021) (USD Million)

Figure 24.        Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

Figure 25.        China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 26.        Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 27.        India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028(USD Million)

Figure 28.        Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 29.        South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 30.        Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)